Literature DB >> 24030748

Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.

Aden Ka-Yin Chan1, Jesse Chung-Sean Pang1, Nellie Yuk-Fei Chung1, Kay Ka-Wai Li1, Wai Sang Poon2, Danny Tat-Ming Chan2, Zhifeng Shi3, Liang Chen3, Liangfu Zhou3, Ho-Keung Ng1.   

Abstract

Combined deletion of chromosomes 1p and 19q is a prognostic marker in oligodendroglial tumors. Recent studies in oligodendroglial tumors have unveiled recurrent mutations of CIC (homolog of Drosophila capicua) and FUBP1 (far upstream element binding protein 1) that are located on 19q13 and 1p31, respectively. However, the impact of CIC and FUBP1 mutations on their protein expressions has not been examined. The aims of this study were to correlate the expression patterns of CIC and FUBP1 with their mutation profiles and to evaluate the clinical relevance of these molecular markers in 55 oligodendroglial tumors diagnosed in 47 adult patients. Using direct sequencing, somatic mutations of CIC and FUBP1 were identified in 47% (22/47) and 16% (7/45) of oligodendroglial tumors, respectively. Immunohistochemical analysis revealed loss of CIC or FUBP1 protein expression in 36% (20/55) and 16% (9/55) of oligodendroglial tumors examined. Somatic mutation was significantly associated with absent protein expression for both genes (CIC, P=0.01; FUBP1, P=0.00001). Four tumors with undetectable CIC mutations exhibited absent CIC expression, suggesting that CIC inactivation could be mediated by mechanisms other than mutations and genomic loss. Univariate survival analysis revealed that 1p/19q codeletion was significantly associated with overall survival (P=0.05). Loss of CIC expression was significantly correlated with shorter progression-free survival (P=0.03), whereas CIC alteration (mutation or null expression) with worse overall survival (P=0.05). Absent FUBP1 expression was linked with unfavorable progression-free survival (P=0.02) and overall survival (P=0.01). In 16 tumors with 1p/19q codeletion, CIC mutation was associated with unfavorable survival (P=0.01). There was a correlation between lack of CIC or FUBP1 expression and poor progression-free survival (P=0.004; P=0.0003). No molecular markers showed association with survival in oligodendroglial tumors lacking 1p/19q codeletion. We conclude that absent CIC and FUBP1 expressions are potential markers of shorter time to recurrence and CIC mutation a potential marker of worse prognosis, especially in tumors carrying 1p/19q codeletion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030748     DOI: 10.1038/modpathol.2013.165

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.

Authors:  Rui Yang; Lee H Chen; Landon J Hansen; Austin B Carpenter; Casey J Moure; Heng Liu; Christopher J Pirozzi; Bill H Diplas; Matthew S Waitkus; Paula K Greer; Huishan Zhu; Roger E McLendon; Darell D Bigner; Yiping He; Hai Yan
Journal:  Cancer Res       Date:  2017-09-22       Impact factor: 12.701

2.  TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Authors:  Aden Ka-Yin Chan; Yu Yao; Zhenyu Zhang; Nellie Yuk-Fei Chung; Joseph Shu-Ming Liu; Kay Ka-Wai Li; Zhifeng Shi; Danny Tat-Ming Chan; Wai Sang Poon; Liangfu Zhou; Ho-Keung Ng
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

Review 3.  The master regulator FUBP1: its emerging role in normal cell function and malignant development.

Authors:  Lydie Debaize; Marie-Bérengère Troadec
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

4.  Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression.

Authors:  Z-H Liu; J-L Hu; J-Z Liang; A-J Zhou; M-Z Li; S-M Yan; X Zhang; S Gao; L Chen; Q Zhong; M-S Zeng
Journal:  Cell Death Dis       Date:  2015-10-15       Impact factor: 8.469

5.  Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors.

Authors:  Fuxin Han; Jinsong Zhang; Shanbo Ma; Xiaoyan Chen; Weiping Liu; Xiaosheng He; Zhou Fei; Yangang Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

Review 6.  Molecular Testing of Brain Tumor.

Authors:  Sung-Hye Park; Jaekyung Won; Seong-Ik Kim; Yujin Lee; Chul-Kee Park; Seung-Ki Kim; Seung-Hong Choi
Journal:  J Pathol Transl Med       Date:  2017-05-12

7.  Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade.

Authors:  Veronique G LeBlanc; Marlo Firme; Jungeun Song; Susanna Y Chan; Min Hye Lee; Stephen Yip; Suganthi Chittaranjan; Marco A Marra
Journal:  J Pathol       Date:  2017-04-26       Impact factor: 7.996

8.  Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.

Authors:  Yan-Xi Li; Zhifeng Shi; Abudumijiti Aibaidula; Hong Chen; Qisheng Tang; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Danny Tat-Ming Chan; Wai Sang Poon; Ying Mao; Jinsong Wu; Liangfu Zhou; Aden Ka-Yin Chan; Ho-Keung Ng
Journal:  Oncotarget       Date:  2016-10-04

9.  Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Authors:  Pei Yang; Jinquan Cai; Wei Yan; Wei Zhang; Yinyan Wang; Baoshi Chen; Guilin Li; Shouwei Li; Chenxing Wu; Kun Yao; Wenbin Li; Xiaoxia Peng; Yongping You; Ling Chen; Chuanlu Jiang; Xiaoguang Qiu; Tao Jiang
Journal:  Neuro Oncol       Date:  2016-03-07       Impact factor: 13.029

10.  Combination genetic signature stratifies lower-grade gliomas better than histological grade.

Authors:  Aden Ka-Yin Chan; Yu Yao; Zhenyu Zhang; Zhifeng Shi; Liang Chen; Nellie Yuk-Fei Chung; Joseph Shu-Ming Liu; Kay Ka-Wai Li; Danny Tat-Ming Chan; Wai Sang Poon; Ying Wang; Liangfu Zhou; Ho-Keung Ng
Journal:  Oncotarget       Date:  2015-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.